4 results
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
We aim to investigate whether this damage results from altered pulmonary blood flow patterns and related increases in shear stress and vascular remodelling. To test our hypothesis we will make use of novel techniques to quantify pulmonary perfusion…
Primary Objective:The primary objective is to evaluate the effects of various doses of BMS-986231 compared to placebo on clinically relevant hypotension (defined by SBP < 90 mm Hg or symptoms of hypotension)Secondary Objectives:* Assess the…
Primary* Evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo. Secondary* Evaluate the effects of BMS-986231 on the left ventricular (LV)…